Email this article 
Serum matrix metalloproteinase type 9 in patients with coronary heart disease
- Authors: Pigarevsky P.V.1, Maltseva S.V.1, Tanyansky D.A.1, Firova E.M.1, Tatarinov A.E.1, Chivikova N.V.1
-
Affiliations:
- Institute of Experimental Medicine
- Issue: Vol 22, No 1 (2022)
- Pages: 37-42
- Section: Original research
- URL: https://journals.eco-vector.com/MAJ/article/view/104665
- DOI: https://doi.org/10.17816/MAJ104665
- ID: 104665
Cite item
Open Access
Access granted
Abstract
BACKGROUND: The study sends to quantify type 9 matrix metalloproteinase in serum in patients with coronary heart disease, since this enzyme is able to provoke an immunoinflammatory process leading to destabilization of atherosclerotic plaque, the development of unstable angina and acute coronary syndrome.
AIM: Is to conduct a comparative analysis of the quantitative content of MMR-9 in serum in patients with coronary heart disease (CHD) with a different course of angina and atherosclerosis and in relatively healthy individuals.
MATERIALS AND METHODS: Blood serum samples of 66 CHD patients were examined. All patients based on clinical examination were divided into 3 groups, depending on the severity of the disease. Quantitative MMR-9 analysis was performed using the Thermo Fisher ELISA kits (BMS2016-2). Determination of the amount of MMR-9 in serum was recorded in the ELX 800 ELISA reader plate. Data processing was carried out using Statistica 6.0 statistical analysis (StatSof, USA). The results were presented as means and mean errors.
RESULTS: The obtained results indicate a significant decrease in the concentration of MMR-9 in the serum of patients with an unstable course of the disease compared to the control group (relatively healthy people). This is probably due to the effect on the content and activity of its MMR-9 inhibitor TIMP-1. Further studies will investigate whether MMR-9 can be considered as a marker of destabilization of atherosclerotic plaque and act as an independent predictor of acute clinical complications in patients with cardiovascular pathology.
CONCLUSIONS: The study made it possible to establish a significant decrease in the concentration of MMR-9 in the serum of patients with an unstable course of atherosclerosis compared to the control group (relatively healthy people). In addition, in patients with an unstable course of atherosclerosis, a tendency to reduce the concentration of this enzyme compared to persons with stable atherosclerosis was revealed.
Full Text
About the authors
Peter V. Pigarevsky
Institute of Experimental Medicine
Author for correspondence.
Email: pigarevsky@mail.ru
ORCID iD: 0000-0002-5906-6771
SPIN-code: 8636-4271
Scopus Author ID: 55404484800
ResearcherId: C-3425-2014
Dr. Sci. (Biol.), Head, Department of General Morphology
Russian Federation, Saint PetersburgSvetlana V. Maltseva
Institute of Experimental Medicine
Email: moon25@rambler.ru
ORCID iD: 0000-0001-7680-8485
SPIN-code: 8367-9096
Scopus Author ID: 6602920398
Cand. Sci. (Biol.), Researcher Associate, Department of General Morphology
Russian Federation, Saint PetersburgDmitry A. Tanyansky
Institute of Experimental Medicine
Email: dmitry.athero@gmail.com
ORCID iD: 0000-0002-5321-8834
SPIN-code: 9303-9445
Scopus Author ID: 53878682400
ResearcherId: G-3307-2015
MD, Cand. Sci. (Med.), Head, Department of Biochemistry
Russian Federation, Saint PetersburgElvira M. Firova
Institute of Experimental Medicine
Email: firova@yandex.ru
MD, Cand. Sci. (Med.), Head of the Clinic Cardiology Department
Russian Federation, Saint PetersburgAlexander E. Tatarinov
Institute of Experimental Medicine
Email: alex2ta@mail.ru
Neurologist, Head of the Clinic Neurological Department
Russian Federation, Saint PetersburgNatalja V. Chivikova
Institute of Experimental Medicine
Email: asa777@list.ru
Doctor of Clinical Laboratory Diagnostics
Russian Federation, Saint PetersburgReferences
- Kakturskij LV. Clinical morphology of acute coronary syndrome. Arkh Patol. 2007;69(4):16–19. (In Russ.)
- Pigarevsky PV, Maltseva SV, Snegova VA. Progressive atherosclerotic lesions in humans. Morphological and immune inflammatory aspects. Cytokines and inflammation. 2013;12(1–2):5–12. (In Russ.)
- Ragino YaI, Chernyavsky AM, Polonskaya IV, et al. Contents of proinflammatory cytokines, chemoattraktants and destructive metalloproteinases in various type of unstable atherosclerotic plaques. Journal of Atherosclerosis and Dyslipidemias. 2011;(1):21–25. (In Russ.)
- Shah PK, Wang L, Sharifi B. New insights into molecular mechanisms of plaque instability. Atherosclerosis Supplements. 2006;7(3):156–157. doi: 10.1016/S1567-5688(06)80612-4
- Nanni S, Melandri G, Hanemaaijer R, et al. Matrixmetalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res. 2007;149(3):137–144. doi: 10.1016/j.trsl.2006.09.001
- Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003;41(4 Suppl S):S15–S22. doi: 10.1016/s0735-1097(02)02834-6
- Severgina LO. Morphogenesis of unstable atherosclerotic plaques and its role in the development of acute coronary syndrome. Arkh Patol. 2005;67(3):51–54. (In Russ.)
- Pigarevsky PV, Maltseva SV, Tatarinov AE, et al. Matrix metalloproteinase type 1 in the blood of patients with coronary heart disease and atherosclerotic lesions in humans. Cytokines and inflammation. 2016;15(1):61–65. (In Russ.)
- Katunina AI, Gerstein ES, Ermilova VD, et al. Content matrix metalloproteinase 2; 7 and 9 in tumors and blood serum of breast cancer patients. Bull Exp Biol Med. 2011;151(3):359–62. doi: 10.1007/s10517-011-1330-z
- Markelov EV, Turmova EP, Silaev AA, et al. The value of the transforming growth factor-β and matrix metalloproteinase-9 in the pathogenesis of atherosclerosis. Russian Journal of Immunology. 2010;4(13)(3):261–266. (In Russ.)
- Vladimirskya TE, Shved IA, Yudina ОА. Expression of extracellular matrix in biomarker of atherosclerotic coronary artery lesions. Journal of Public Health. Belarus. 2016;(7):4–9. (In Russ.)
- Provatorov SI. Systemic manifestations of inflammatory reaction in coronary stentirovanii: prognostic significance and possibilities for pharmacological effects [dissertation]. Moscow; 2014. (In Russ.)
- Govorin AV, Racina EV, Sokolova NA, Fetisova NV. The values of matrix metalloprotease-9 and tissue metalloprotease inhibitor-1 in acute myocardial infarction with aneurysm formation. Russian Journal of Cardiology. 2014;19(7):87–90. (In Russ.) doi: 10.15829/1560-4071-2014-7-87-90
- Gening SO, Abakumova TV. A study of matrix of serum metalloproteinase with the progression of ovarian cancer. Advances in current natural sciences. 2013;(9):26–27. (In Russ.)
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).